Cette recherche s'applique uniquement aux ressources en bibliothèque.
4 résultats
Trier par:
Ajouter à la liste:

Facette sélectionnée


Étendre à toutes les références (sans texte intégral)
    • Article
    Sélectionner

    Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials

    Aneheim, Emma, Albertsson, Per, Bäck, Tom, Jensen, Holger, Palm, Stig, Lindegren, Sture
    Scientific reports, 14 July 2015, Vol.5, pp.12025 [Revue évaluée par les pairs]
    MEDLINE/PubMed (U.S. National Library of Medicine)
    Disponible
    Plus…
    Titre: Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials
    Auteur: Aneheim, Emma; Albertsson, Per; Bäck, Tom; Jensen, Holger; Palm, Stig; Lindegren, Sture
    Sujet: Clinical Trials As Topic ; Multicenter Studies As Topic ; Astatine -- Chemistry ; Radiopharmaceuticals -- Chemistry
    Description: To facilitate multicentre clinical studies on targeted alpha therapy, it is necessary to develop an automated, on-site procedure for conjugating rare, short-lived, alpha-emitting radionuclides to biomolecules. Astatine-211 is one of the few alpha-emitting nuclides with appropriate chemical and physical properties for use in targeted therapies for cancer. Due to the very short range of the emitted α-particles, this therapy is particularly suited to treating occult, disseminated cancers. Astatine is not intrinsically tumour-specific; therefore, it requires an appropriate tumour-specific targeting vector, which can guide the radiation to the cancer cells. Consequently, an appropriate method is required for coupling the nuclide to the vector. To increase the availability of astatine-211 radiopharmaceuticals for targeted alpha therapy, their production should be automated. Here, we present a method that combines dry distillation of astatine-211 and a synthesis module for producing radiopharmaceuticals...
    Fait partie de: Scientific reports, 14 July 2015, Vol.5, pp.12025
    Identifiant: 2045-2322 (E-ISSN); 26169786 Version (PMID); 10.1038/srep12025 (DOI)

    • Article
    Sélectionner

    Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials

    Aneheim, Emma, Albertsson, Per, Bäck, Tom, Jensen, Holger, Palm, Stig, Lindegren, Sture
    Scientific Reports, 12/2015, Vol.5(1) [Revue évaluée par les pairs]
    Nature Publishing Group (via CrossRef)
    Disponible
    Plus…
    Titre: Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials
    Auteur: Aneheim, Emma; Albertsson, Per; Bäck, Tom; Jensen, Holger; Palm, Stig; Lindegren, Sture
    Fait partie de: Scientific Reports, 12/2015, Vol.5(1)
    Identifiant: 2045-2322 (E-ISSN); http (DOI)

    • Article
    Sélectionner

    Automated astatination of biomolecules - a stepping stone towards multicenter clinical trials

    Aneheim, Emma, Albertsson, Per, Bäck, Tom, Jensen, Holger, Palm, Stig, Lindegren, Sture
    Scientific Reports (Nature Publisher Group), Jul 2015, Vol.5, p.12025 [Revue évaluée par les pairs]
    © ProQuest LLC All rights reserved, Medical Database, ProQuest Science Journals, Health & Medical Collection (Alumni edition), Medical Database (Alumni edition), Science Database (Alumni edition), Health & Medical Collection, Biological Science Database, Publicly Available Content Database, ProQuest Biological Science Collection, ProQuest Central, ProQuest Hospital Collection, ProQuest Natural Science Collection, Hospital Premium Collection (Alumni edition), ProQuest SciTech Collection, ProQuest Health & Medical Complete, ProQuest Medical Library, Natural Science Collection, ProQuest Central (new), ProQuest Central K-12, ProQuest Central Korea, SciTech Premium Collection, Health Research Premium Collection, Health Research Premium Collection (Alumni edition), ProQuest Central Essentials, ProQuest One Academic
    Disponible
    Plus…
    Titre: Automated astatination of biomolecules - a stepping stone towards multicenter clinical trials
    Auteur: Aneheim, Emma; Albertsson, Per; Bäck, Tom; Jensen, Holger; Palm, Stig; Lindegren, Sture
    Sujet: Clinical Trials ; Tumors ; Antibodies ; Automation ; Cancer ; Radioisotopes
    Description: To facilitate multicentre clinical studies on targeted alpha therapy, it is necessary to develop an automated, on-site procedure for conjugating rare, short-lived, alpha-emitting radionuclides to biomolecules. Astatine-211 is one of the few alpha-emitting nuclides with appropriate chemical and physical properties for use in targeted therapies for cancer. Due to the very short range of the emitted α-particles, this therapy is particularly suited to treating occult, disseminated cancers. Astatine is not intrinsically tumour-specific; therefore, it requires an appropriate tumour-specific targeting vector, which can guide the radiation to the cancer cells. Consequently, an appropriate method is required for coupling the nuclide to the vector. To increase the availability of astatine-211 radiopharmaceuticals for targeted alpha therapy, their production should be automated. Here, we present a method that combines dry distillation of astatine-211 and a synthesis module for producing radiopharmaceuticals...
    Fait partie de: Scientific Reports (Nature Publisher Group), Jul 2015, Vol.5, p.12025
    Identifiant: 20452322 (E-ISSN); 10.1038/srep12025 (DOI)

    • Article
    Sélectionner

    Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials

    Emma Aneheim, Per Albertsson, Tom Bäck, Holger Jensen, Stig Palm, Sture Lindegren
    Scientific Reports, 2015, Vol.5 [Revue évaluée par les pairs]
    Nature Publishing Group
    Disponible
    Plus…
    Titre: Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials
    Auteur: Emma Aneheim; Per Albertsson; Tom Bäck; Holger Jensen; Stig Palm; Sture Lindegren
    Fait partie de: Scientific Reports, 2015, Vol.5
    Identifiant: (ISSN); 2045-2322 (E-ISSN); 10.1038/srep12025 (DOI)